Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541564 | 1.00 | TSHR (0.38) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL24731109 | 1.00 | TSHR (0.38) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL20466942 | 0.87 | PER2 (0.35) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL4338411 | 0.83 | PER2 (0.37) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL12646289 | 0.83 | CHRM2 (0.38) | TSHRHSD17B10CHRM2CHRM4CHRM5 | |
| SCHEMBL19420021 | 0.79 | ALDH1A1 (0.38) | TSHRHSD17B10CHRM2CHRM4CHRM5 | |
| SCHEMBL2347093 | 0.78 | CHRM2 (0.35) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL13274981 | 0.78 | CHRM2 (0.35) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL13280450 | 0.78 | CHRM2 (0.35) | TSHRHSD17B10POLBGAANPSR1 | |
| SCHEMBL13075650 | 0.77 | KMT2A (0.38) | TSHRHSD17B10POLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5267532-A | pH-indicating material and cat litter containing same | ANITOX CORPORATION (US) | 1993-12-07 | — | — | US | claimed |
| EP-0569232-A1 | pH-indicating material and cat litter containing same | ANITOX CORPORATION (US) | 1993-11-10 | — | — | EP | claimed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2020205835-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205832-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-5578219-A | IMPROVED ABSORPTION AND FLOCCULATION PROPERTIES, OIL WELL DRILLING APPLICATIONS, COSMETIC AND ANTI-POLLUTION APPLICATIONS | AMCOL INTERNATIONAL CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| US-5556547-A | IMPROVED ABSORBENCY, DRILLING FLUIDS, WASTE WATER TREATMENT | AMCOL INTERNATIONAL CORPORATION (US) | 1996-09-17 | — | — | US | disclosed |
| US-5476142-A | Applying a slurry of a water-swellable sodium bentonite clay, a non water-swellable filler and a water soluble polymer | AMERICAN COLLOID COMPANY (US) | 1995-12-19 | — | — | US | disclosed |
| CN-1105286-A | Method of improving the contaminant resistance of a smectite clay by rewetting and impregnating the clay with a water-soluble poly mer, and redrying the polymer-impregnated clay | AMERICAN COLLOID CO (US) | 1995-07-19 | — | — | CN | disclosed |
| US-5407879-A | Promoting absorption or adsorption by treating with aqueous polymer solution, then drying to controlled moisture content | AMERICAN COLLOID COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0645181-A2 | Method of improving the contaminant resistance of a smectite clay | AMCOL INTERNATIONAL CORPORATION (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0610008-A1 | Multi-layer waterproofing articles including a layer of water-soluble polymer and method | AMCOL INTERNATIONAL CORPORATION (US) | 1994-08-10 | — | — | EP | disclosed |
| US-5267532-A | pH-indicating material and cat litter containing same | ANITOX CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0569232-A1 | pH-indicating material and cat litter containing same | ANITOX CORPORATION (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | TSHR 4060/4885HSD17B10 2675/4885POLB 626/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | TSHR 4000/4885HSD17B10 233/4885POLB 4692/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | TSHR 562/4885HSD17B10 1814/4885POLB 4018/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | TSHR 3552/4885HSD17B10 2182/4885POLB 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.